What is topiramateTopiramate is a prescription drug used to treat seizures, migraines, tremors, and sometimes obesity.Talk to your doctor about whether topiramate is right for you.
While often depicted in media by people suddenly collapsing or convulsing uncontrollably, seizures in actuality take on a variety of different forms that range from brief muscle loss to merely short episodes of confusion. Seizures are rarely life-threatening on their own accord; the loss of consciousness or muscle control that accompanies some seizures, though, can lead to serious injuries or death. Most seizures can be effectively treated with medications like topiramate.
While there are some common side effects associated with topiramate, it is important to remember that your doctor prescribed this medication because they believe its ability to suppress your seizures outweighs any adverse side effects it may cause.
Being at the peak of its popularity, Topamax is available in the vast majority of online pharmacies. However, if you wish to make your treatment course safe, effective and harmless, select a reliable web-based drugstore that offers high quality drugs. Apart from an effective medication you will receive convenient services, fast delivery, low prices and other benefits.
Topiramate prescription medication, marketed under brand names such as Qudexy XR and Topamax, is a medication used in the management migraines and certain types of epilepsy. Topiramate medication belongs to a class of medications known as antiepileptic drugs. The exact mechanism of action of how topiramate tablets work is unknown but may center around the blocking of sodium channels and effects on GABA-A receptors. Topiramate medication may also impact the glutamate receptor and block carbonic anhydrase to achieve its effects. Like erenumab (Aimovig), fremanezumab (Ajovy) and galcanezumab-gnlm (Emgality) and unlike rizatriptan (Maxalt) and sumatriptan (Imitrex), topiramate prescription medication is used for preventative rather than acute treatment of migraines. There are anecdotal reports of using topiramate for weight loss but, at this time, there is no official approval for that indication.
In adults, a frequently used topiramate dosage is topiramate 25 mg daily which is then titrated over the course of the weeks to the patient's symptoms. Ultimately, the prescribed topiramate dose is dependent on the health needs of the patient and the judgement of the medical provider. Following oral administration, topiramate typically reaches peak plasma levels in roughly two hours in healthy people. The elimination half-life of topiramate is under 24 hours and most of the elimination occurs primarily through the urine. While branded topiramate is expensive, generic topiramate is affordable, costing under 20 cents per topiramate 50 mg tablet at many pharmacies in the United States. Topiramate coupons are available online as well and some insurance plans may cover the cost of a topiramate tablet prescription.
Topiramate is a prescription medication in the United States. Because of this designation, one cannot just buy topiramate online as the first step is consulting a medical provider and getting a topiramate prescription. For this reason, topiramate OTC (over the counter) is not available at pharmacies, either. People who need a topiramate prescription, however, can use Push Health to connect with a medical provider who can prescribe topiramate tablets, including generic topiramate 25 mg, topiramate 50 mg and topiramate 100 mg medication, when appropriate to do so.
Topiramate prescription medication can cause side effects when used and concerns should be discussed with one's medical provider and pharmacist before using the medication. Side effects that may result from topiramate tablet use include weight loss, loss of appetite, mood swings, dizziness, memory issues, flushing and nervous feelings. Topiramate medication should generally not be used by people with glaucoma or mood disorders such as suicidal ideation. Topiramate can increase the risk of getting kidney stones. Topiramate medication and alcohol should not be used together. People with a known hypersensitivity or allergy to topiramate prescription tablets or ingredients in the formulation should not use topiramate medication.
Do not take Qsymia if you are pregnant, planning to become pregnant, or become pregnant during Qsymia treatment; have glaucoma; have thyroid problems (hyperthyroidism); are taking certain medicines called monoamine oxidase inhibitors (MAOIs) or have taken MAOIs in the past 14 days; are allergic to topiramate, sympathomimetic amines such as phentermine, or any of the ingredients in Qsymia. See the end of the Medication Guide for a complete list of ingredients in Qsymia.
Visual field defects (independent of elevated intraocular pressure) have been reported in clinical trials and in postmarketing experience in patients receiving topiramate. In clinical trials, most of these events were reversible after topiramate discontinuation. If visual problems occur at any time during treatment, consider discontinuing Qsymia.
Topiramate works in three ways to prevent epileptic fits. Firstly, it enhances the activity of a neurotransmitter called GABA in the brain. Neurotransmitters are chemicals that are stored in nerve cells and are involved in transmitting messages between the nerve cells. GABA is a neurotransmitter that acts as a natural calming agent. It keeps the nerve activity in the brain in balance. As topiramate enhances the action of GABA, it helps calm the nerve activity in the brain.
Maternal doses of topiramate up to 200 mg daily produce relatively low levels in infant serum. Sedation and diarrhea have been reported occasionally in breastfed infants, but most infants tolerate the drug in milk well. In a few infants, no long-term adverse effects on growth and development have been seen. Monitor the infant for diarrhea, drowsiness, irritability, adequate weight gain, and developmental milestones, especially in younger, exclusively breastfed infants and when using combinations of anticonvulsant or psychotropic drugs.
Maternal Levels. Three women were taking oral topiramate daily. One taking 150 mg daily had an average milk level of 2.3 mg/L on day 24 postpartum. A mother taking 200 mg daily had average milk levels of 4.8 mg/L on day 20 postpartum and 4.6 mg/L on day 97 postpartum. The third woman who was taking 200 mg daily had average milk level 610 mcg/L on day 14 postpartum and 1.2 mg/L on day 27 postpartum. The authors estimated that the infants received doses between 0.1 and 0.7 mg/kg daily, which was between 3 and 23% of the mother's weight-adjusted dose.
A nursing mother was taking 100 mg of topiramate daily. Topiramate was detected in breastmilk at a concentration of 5.3 mg/L at an unspecified time with respect to the dose. The authors estimated that the infant might have received 35% of the maternal weight-adjusted dosage, although their calculation method is unclear. Using the milk level of 5.3 mg/L, the infant would have received 56% of the maternal weight-adjusted dosage.
Twenty-two women taking topiramate during pregnancy and postpartum had measurements of topiramate in colostrum taken on day 3 or 4 postpartum for routine monitoring. Colostrum topiramate levels averaged 3.5 mg/L. Another 5 mothers had milk samples taken between day 7 and 30 (mean 16 days) postpartum. Their milk levels averaged 5.9 mg/L.
Infant Levels. Three infants were breastfed from birth while their mothers were taking oral topiramate for epilepsy. Serum levels in a 24-day-old infant whose mother was taking 150 mg daily were about 475 mcg/L. Another infant whose mother was taking 200 mg daily had an average serum level of 594 mcg/L at 20 days of age and 713 mcg/L at 97 days of age. A third infant whose mother was taking 200 mg daily had undetectable (305 mcg/L) serum concentrations, but none had quantifiable (>949 mcg/L) serum topiramate concentrations.
A woman was taking 175 mg of topiramate daily. On day 26 postpartum, her breastfed infant had a serum level of 0.8 mg/L at 3 hours after a dose, which was 15% of the mother's simultaneous serum level.
Nineteen infants whose mothers were taking topiramate during pregnancy and postpartum had measurements of topiramate in serum taken on day 3 or 4 postpartum for routine monitoring. The average serum concentration was 1.1 mg/L. Another 6 infants had serum topiramate levels taken between day 7 and 30 (mean 16 days) postpartum. Their serum levels averaged 2.2 mg/L. Infant serum levels averaged 51% of simultaneous maternal serum levels.
An exclusively breastfed infant whose mother was taking topiramate 300 mg, levetiracetam 2 grams, and valproate 1.8 grams daily during pregnancy and lactation appeared healthy to the investigators throughout the 6- to 8-week study period.
One woman breastfed her infant for 13 months while she was taking topiramate for epilepsy. She took a daily dosage of 150 to 175 mg for the first 6 months, then 200 mg daily. At 1 year of age, the infant was developing normally and both parents stated that no side effects such as tiredness had been observed in the infant.
A woman who took topiramate 300 mg daily throughout pregnancy delivered a normal, healthy infant. She reportedly breastfed her infant exclusively for 8 months at which time no adverse drug effects or neurodevelopmental delay were noted by the infant's pediatrician.
The breastfed infant of a mother who was taking 100 mg of topiramate daily developed watery, foamy stools with 8 to 10 bowel movements daily at 40 days of age. The infant's rate of weight gain also declined. Topiramate was detected in breastmilk at a relatively high concentration. Two weeks later, breastfeeding was discontinued. Within 24 hours, the stool frequency declined to 2 to 3 times daily, more solid and the color and odor normalized. Topiramate was the probable cause of the d